Sign up to save your data!
Some tips to help get started:
Processing...
There are 137 active trials for advanced/metastatic colon cancer. Click on a trial to see more information.
137 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with advanced, unresectable, or metastatic colorectal carcinoma (in Europe and US), as well as gastric carcinoma or pancreatic ductal adenocarcinoma (in the US), who have progressed after standard therapies or are ineligible for them, to receive BI 765049, a bispecific T-cell engager targeting B7-H6 on tumor cells and CD3 on T cells. The study investigates different dosing regimens of parenteral BI 765049, with treatment continuing in the absence of progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT06882746
HealthScout AI summary: Adults with unresectable metastatic colorectal adenocarcinoma who have progressed after at least two prior lines of therapy and have ECOG 0-1 are eligible to receive investigational JNJ-89402638 (mechanism of action not disclosed); the study uses dose escalation and expansion to assess safety and determine the recommended phase 2 dose.
ClinicalTrials.gov ID: NCT06663319
HealthScout AI summary: This trial enrolls adults with advanced, measurable solid tumors (ECOG 0-1) to receive monotherapy with TORL-3-600, an antibody-drug conjugate targeting cadherin 17 (CDH17) with an MMAE payload, particularly relevant for patients with GI cancers such as colorectal, gastric, or pancreatic cancer. Key exclusions include active brain metastases, significant comorbidities, and recent prior cancers.
ClinicalTrials.gov ID: NCT05948826
HealthScout AI summary: Eligible patients have advanced or metastatic colorectal or gastroesophageal adenocarcinoma with prior treatment failure, and will receive oral trifluridine/tipiracil plus talazoparib, a PARP inhibitor targeting DNA repair, to evaluate safety and dosing. Certain biomarker-defined cohorts are also included.
ClinicalTrials.gov ID: NCT04511039
HealthScout AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors—primarily colorectal cancer but also including HCC, TNBC, NSCLC, ovarian cancer, melanoma, cholangiocarcinoma, and synovial sarcoma—who have progressed on or are ineligible for standard treatments. Patients receive intravenous ST316, a β-catenin/BCL9 interaction inhibitor targeting aberrant WNT/β-catenin signaling, as monotherapy or in combination with standard regimens in CRC.
ClinicalTrials.gov ID: NCT05848739
HealthScout AI summary: This study is enrolling adults with advanced, relapsed, or refractory adenoid cystic carcinoma or colorectal carcinoma who have exhausted standard therapies, to receive the oral MYB mRNA-targeting inhibitor RGT-61159. RGT-61159 degrades MYB mRNA via altered splicing and nonsense-mediated decay, aiming to reduce MYB protein in these cancers.
ClinicalTrials.gov ID: NCT06462183
HealthScout AI summary: Eligible patients are adults with metastatic or unresectable solid tumors harboring a G12V mutation in KRAS, NRAS, or HRAS who are HLA-A*11:01 positive and have progressed on or declined standard therapies. Treatment involves lymphodepleting chemotherapy followed by infusion of autologous peripheral blood lymphocytes genetically modified to express a murine T-cell receptor targeting the G12V RAS mutation, along with high-dose aldesleukin.
ClinicalTrials.gov ID: NCT03190941
HealthScout AI summary: This trial enrolls adults with advanced cancers and predominant hepatic metastases, including a cohort with metastatic colorectal cancer and another with liver metastases harboring PI3K pathway activation, testing the addition of the investigational NovoTTF-100L(P) system (tumor treating electric fields targeting mitosis) to standard chemotherapy and bevacizumab. Treatments include FOLFOX6 plus bevacizumab for colorectal cancer, or pegylated liposomal doxorubicin, temsirolimus (an mTOR inhibitor), and bevacizumab for PI3K pathway-activated cases.
ClinicalTrials.gov ID: NCT03203525
HealthScout AI summary: This trial enrolls adults with HLA-A*11:01-positive, metastatic or unresectable solid tumors harboring a G12D mutation in KRAS, NRAS, or HRAS who have progressed on standard therapy, and treats them with lymphodepleting chemotherapy followed by autologous T-cells engineered with a murine T-cell receptor targeting the G12D RAS mutation, plus high-dose IL-2. The investigational therapy specifically redirects T-cells to recognize and kill G12D-mutant RAS cancer cells presented by HLA-A*11:01.
ClinicalTrials.gov ID: NCT03745326
HealthScout AI summary: This trial enrolls adults with advanced, relapsed or refractory solid tumors known to express ADAM9—including NSCLC adenocarcinoma, cholangiocarcinoma, colorectal, and pancreatic cancers—to receive MGC028, an investigational antibody-drug conjugate targeting ADAM9 with a topoisomerase I inhibitor payload. Patients must have measurable disease and accessible tissue for testing; prior treatment limits apply in expansion cohorts.
ClinicalTrials.gov ID: NCT06723236
